170 related articles for article (PubMed ID: 29732557)
1. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.
Cao J; Pontes KC; Heijkants RC; Brouwer NJ; Groenewoud A; Jordanova ES; Marinkovic M; van Duinen S; Teunisse AF; Verdijk RM; Snaar-Jagalska E; Jochemsen AG; Jager MJ
J Pathol; 2018 Aug; 245(4):433-444. PubMed ID: 29732557
[TBL] [Abstract][Full Text] [Related]
2. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.
Sha MQ; Zhao XL; Li L; Li LH; Li Y; Dong TG; Niu WX; Jia LJ; Shao RG; Zhen YS; Wang Z
Cell Death Dis; 2016 Nov; 7(11):e2486. PubMed ID: 27882937
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
4. Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Shi Y; Tao M; Wang Y; Zang X; Ma X; Qiu A; Zhuang S; Liu N
J Pathol; 2020 Jan; 250(1):79-94. PubMed ID: 31579944
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
6. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.
Fan T; Jiang S; Chung N; Alikhan A; Ni C; Lee CC; Hornyak TJ
Mol Cancer Res; 2011 Apr; 9(4):418-29. PubMed ID: 21383005
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Oki S; Sone K; Oda K; Hamamoto R; Ikemura M; Maeda D; Takeuchi M; Tanikawa M; Mori-Uchino M; Nagasaka K; Miyasaka A; Kashiyama T; Ikeda Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Fukayama M; Osuga Y; Fujii T
Oncotarget; 2017 Jun; 8(25):40402-40411. PubMed ID: 28418882
[TBL] [Abstract][Full Text] [Related]
8. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis.
Jiang Y; Xiang C; Zhong F; Zhang Y; Wang L; Zhao Y; Wang J; Ding C; Jin L; He F; Wang H
Theranostics; 2021; 11(1):361-378. PubMed ID: 33391480
[No Abstract] [Full Text] [Related]
9. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
10. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
[TBL] [Abstract][Full Text] [Related]
11. linc01088 promotes cell proliferation by scaffolding EZH2 and repressing p21 in human non-small cell lung cancer.
Liu JQ; Feng YH; Zeng S; Zhong MZ
Life Sci; 2020 Jan; 241():117134. PubMed ID: 31811854
[TBL] [Abstract][Full Text] [Related]
12. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
13. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
[TBL] [Abstract][Full Text] [Related]
14. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
15. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
[TBL] [Abstract][Full Text] [Related]
16. The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Wang Y; Chen SY; Karnezis AN; Colborne S; Santos ND; Lang JD; Hendricks WP; Orlando KA; Yap D; Kommoss F; Bally MB; Morin GB; Trent JM; Weissman BE; Huntsman DG
J Pathol; 2017 Jul; 242(3):371-383. PubMed ID: 28444909
[TBL] [Abstract][Full Text] [Related]
17. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
18. Repression of PDK1- and LncRNA HOTAIR-Mediated EZH2 Gene Expression Contributes to the Enhancement of Atractylenolide 1 and Erlotinib in the Inhibition of Human Lung Cancer Cells.
Xiao Q; Zheng F; Tang Q; Wu JJ; Xie J; Huang HD; Yang XB; Hann SS
Cell Physiol Biochem; 2018; 49(4):1615-1632. PubMed ID: 30223276
[TBL] [Abstract][Full Text] [Related]
19. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
20. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
